ALG-000184, Publications ALG-000184, a Capsid Assembly Modulator, Demonstrates Superior Antiviral Activity in Combination with Entecavir Compared to Entecavir in HBeAg Positive Subjects with Chronic Hepatitis B infection
Publication, Publications The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir
ALG-097558, Publications Preclinical Evaluation of ALG-097558:A Novel, Orally Bioavailable Pan-Coronavirus 3CLpro Inhibitor for the Treatment of COVID-19
ALG-000184, Publications The Prodrug of a Novel Capsid Assembly Modulator (CAM), ALG-000184, Demonstrates a Favorable Nonclinical Toxicokinetic and Toxicology Profile for the Treatment of Chronic Hepatitis B (CHB)
Preclinical, Publications Discovery of Liver-targeted Oral PD-L1 Small Molecule Inhibitors for the Treatment of Chronic Hepatitis B and Liver Cancers
ALG-000184, Publications Safety, Pharmacokinetics (PK), and Antiviral Activity of the Capsid Assembly Modulator (CAM) ALG-000184 in Subjects with HBeAg Positive Chronic Hepatitis B (CHB)
ALG-055009, Publications Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Oral Doses of ALG-055009, a Thyroid Hormone Receptor Beta Agonist, in Hyperlipidaemic Subjects
Other, Publications Nonclinical efficacy, pharmacokinetic profile and pharmacokinetic/pharmacodynamic (PK/PD) correlation of ALG-125755, a GalNAc conjugated siRNA, for functional cure of chronic hepatitis B
Preclinical, Publications HAP Class I Capsid Assembly Modulators Clear Hepatitis B Virus-Infected Hepatocytes Through Core-dependent Hepatocyte Death and Subsequent Proliferation
Preclinical, Publications Non-HAP class I capsid assembly modulators have distinct profiles and a differentiated mechanism of action